MCT Oil for Infants: Medical Uses and Safety

MCT oil is not a routine supplement for healthy infants but serves as a targeted medical intervention for specific conditions, primarily fat malabsorption syndromes, certain inborn metabolic disorders, and drug-resistant epilepsy. In these clinical settings, MCT oil takes advantage of a biochemical shortcut: medium-chain fatty acids can be absorbed and burned for energy without some of the digestive machinery that longer fats require, which matters when that machinery is impaired. The evidence behind these uses is real but uneven, and the oil carries nutritional trade-offs that make unsupervised use risky.

Why Medium-Chain Fats Absorb Differently

Most dietary fat consists of long-chain fatty acids, which require bile salts to break them down, then travel through the lymphatic system before reaching the bloodstream. Medium-chain fatty acids skip much of that process. They are absorbed directly into the portal vein and carried straight to the liver, bypassing the lymphatic route entirely.¹ Once in the liver, medium-chain fatty acids enter the mitochondria without needing the carnitine shuttle, a transport step that long-chain fats depend on.² These two shortcuts mean MCTs can be digested, absorbed, and converted to energy even when an infant’s bile flow is blocked, the gut is immature, or a metabolic enzyme is missing.

This absorption advantage also shows up in the stomach. In premature infants, feedings containing MCTs emptied from the stomach faster than feedings with long-chain fats, which can help infants who struggle with delayed gastric emptying and feeding intolerance.³

Preterm and Low Birth Weight Infants

Premature babies are born with an immature digestive system, including low bile salt production and reduced pancreatic enzyme activity. Because of this, they struggle to absorb long-chain fats. MCT oil or MCT-enriched formulas have been used for decades to bridge that gap. Early clinical work showed that preterm infants on MCT formula absorbed fat far more efficiently, jumping from about 83% to 97% fat absorption, with correspondingly better weight gain.⁴ A randomized trial of MCT oil massage in preterm infants also found measurably greater weight gain compared to control groups within the first week of life.⁵

But the picture gets more complicated when you look at larger reviews. A Cochrane systematic review pooling data from multiple trials found no significant difference in short-term weight gain, length, or head circumference between preterm infants on high-MCT versus low-MCT formulas.⁶ And a recent prospective cohort study reported a troubling association: preterm infants who received MCT supplementation had a greater drop in weight-for-age scores and longer hospital stays, with only about 9% maintaining adequate weight by discharge.⁷

This seeming contradiction has a likely explanation. Infants who are given MCT supplementation in hospitals tend to be the sickest babies, the ones with the worst feeding tolerance and the most immature guts. Their poorer outcomes probably reflect the severity of their underlying conditions, not harm from the oil itself. Still, the Cochrane review’s findings make it clear that simply swapping long-chain fats for MCTs in formula does not automatically accelerate growth in preterm infants as a group. MCT is useful when there is a clear absorption deficit, not as a blanket growth booster.

One area where early data looks more promising is head circumference. A randomized trial of oral MCT oil in low birth weight neonates found significantly greater head circumference growth over four weeks compared to controls, suggesting a potential benefit for brain development in this vulnerable group.⁸ That said, this is a single trial, and the finding needs replication before strong conclusions can be drawn.

Cholestatic Liver Disease and Biliary Atresia

When bile cannot flow normally from the liver to the intestine, long-chain fats go largely undigested. This is exactly the situation in biliary atresia, a condition where bile ducts are damaged or absent, and in other forms of cholestatic liver disease. MCT oil has been a mainstay of nutritional support for these infants because it bypasses the need for bile-dependent digestion. A scoping review of cholestatic liver disease in children confirmed that fat absorption was greater with MCT supplementation in every study that measured it.⁹

Yet better fat absorption does not automatically translate to better growth. An analysis of the largest biliary atresia cohort ever studied, involving 200 patients, found no association between the percentage of MCT in an infant’s diet and their growth, nutritional status, or clinical outcomes. Counterintuitively, there was even an inverse association between MCT dose and growth.¹⁰ As with preterm supplementation, the likely explanation is confounding: sicker infants get more MCT, and their disease severity drives their poor growth. But it also means clinicians cannot assume that more MCT equals better results. The dose and proportion of MCT in an infant’s diet need to be carefully calibrated, not maximized.

Chylous Disorders

Some infants are born with or develop conditions where lymphatic fluid leaks into body cavities, such as chylothorax (lymphatic fluid in the chest) or chylous ascites (in the abdomen). These leaks are worsened by dietary long-chain fats, because long-chain fatty acids travel through the lymphatic system after absorption and increase lymph flow. MCT’s lymphatic bypass makes it a logical dietary intervention: by replacing long-chain fats with MCTs, chyle production drops and the body has a chance to heal the leak.

This principle has even been applied prenatally. Case reports describe pregnant women placed on an MCT-based diet when their unborn babies developed fetal pleural effusions, with resolution of the fluid buildup before birth.¹ After birth, infants with chylothorax are typically transitioned to MCT-rich formula until the lymphatic leak resolves, which can take weeks to months.

Long-Chain Fatty Acid Oxidation Disorders

A group of inherited metabolic conditions known as long-chain fatty acid oxidation disorders (LC-FAODs) prevent the body from properly breaking down long-chain fats for energy. During periods of fasting or illness, affected infants can develop dangerously low blood sugar, muscle breakdown, and potentially fatal cardiac problems. MCT oil is a cornerstone of dietary management for these disorders because medium-chain fats use a different metabolic pathway that remains functional.¹¹

Dietary guidelines for LC-FAODs typically restrict long-chain fat to about 10% of total energy intake while supplementing with MCT at 10 to 25% of total energy. These infants also need careful attention to essential fatty acid intake, with linoleic acid and linolenic acid supplied in specific proportions.¹² Because these conditions are identified through newborn screening in many countries, affected infants are usually started on an MCT-supplemented feeding regimen within the first days of life.

MCT oil has also been used for rarer metabolic conditions. In DGAT-1 deficiency, a condition that causes severe congenital diarrhea, a treatment plan built around C8 (caprylic acid) MCT oil along with essential fatty acid supplementation put one infant into full remission, with weight normalizing by 24 months of age.¹³

Drug-Resistant Epilepsy

The ketogenic diet has been used to treat seizures in children since the 1920s, and the MCT variant of this diet has been in use since the 1970s. In the MCT ketogenic diet, MCT oil supplies a large share of calories because medium-chain fats are more efficiently converted into ketone bodies than long-chain fats. This means the diet can include slightly more protein and carbohydrate while still maintaining ketosis, which tends to make it more tolerable for children.

A prospective study following 48 children with therapy-resistant epilepsy on the MCT-ketogenic diet found that about 17% were responders (meaning their seizure frequency dropped by at least half) at three months, one year, and two years. The highest response rate, roughly 23%, was observed at six to nine months.¹⁴ These numbers are modest, but the children enrolled in ketogenic diet studies have already failed multiple medications, so any meaningful seizure reduction is significant. Most children who benefit see improvements in seizure severity as well, not just frequency. The dropout rate is substantial: only about a quarter of patients were still on the diet at one year, and fewer than a quarter at two years, reflecting the difficulty of maintaining such a restrictive eating pattern.

The Risk of Essential Fatty Acid Deficiency

MCT oil provides energy efficiently, but it contains no essential fatty acids. Linoleic acid and alpha-linolenic acid, the two fats the human body cannot make on its own, are long-chain fatty acids found in vegetable oils, breast milk, and standard infant formulas. When MCT replaces a large proportion of dietary fat, these essential fats can be squeezed out.

This is not a theoretical concern. A study of four infants with hepatobiliary disease receiving high-MCT formula found that all four developed biochemical signs of essential fatty acid deficiency, including abnormal blood fatty acid profiles. One of the infants may have experienced growth failure as a result.¹⁵ The authors recommended that infants on MCT-based formulas receive well above the standard minimum of linoleic acid to prevent this problem. The same risk applies to fat-soluble vitamins A, D, E, and K, which require some long-chain fat for proper absorption.¹⁶

This is the central safety trade-off with MCT use in infants. The oil solves one problem (energy from fat absorption) while potentially creating another (micronutrient and essential fatty acid depletion). Medical teams managing infants on high-MCT diets monitor blood fatty acid levels and supplement essential fats and vitamins accordingly. Parents should never place an infant on a high-MCT regimen without medical supervision, because getting the balance wrong can cause real harm.

How MCT in Formula Differs from MCT in Breast Milk

Human breast milk does contain medium-chain fatty acids, but they are packaged differently than the MCT oil used in infant formulas. In breast milk, medium-chain fatty acids sit on triglyceride molecules alongside long-chain fatty acids, forming mixed structures called medium-and-long-chain triacylglycerols (MLCTs). Most commonly, a single medium-chain fatty acid is paired with two long-chain fatty acids on the same molecule.¹⁷

Infant formulas enriched with MCT oil, by contrast, typically use pure MCT where all three fatty acid positions on the triglyceride backbone are filled with medium-chain fatty acids. This structural difference affects how digestive enzymes interact with the fat. Research comparing human milk to MCT-enriched formulas found that the proportions of these different triglyceride types did not match: formulas had far higher proportions of pure MCT (three medium-chain fatty acids per molecule) than breast milk does.¹⁸ Whether this structural mismatch has meaningful clinical consequences for healthy infants is still an open question, but it underscores that MCT-enriched formula is a functional approximation, not a copy, of what nature provides.

Effects on the Infant Gut

One concern that comes up around any dietary intervention in premature infants is whether it disrupts the developing gut microbiome. A pilot study in premature infants found that MCT supplementation did not significantly change the diversity or composition of gut bacteria. Reassuringly, there was no increase in Enterobacteriaceae, a bacterial family that includes several potential pathogens associated with necrotizing enterocolitis, a serious intestinal disease in premature babies. The study did observe a hint that MCT might reduce fungal colonization, though this needs further investigation.¹⁹

Gastrointestinal tolerance is generally acceptable at the doses used in clinical settings, though some infants experience loose stools or abdominal discomfort when MCT oil is introduced. Starting at lower doses and increasing gradually is standard practice. The faster gastric emptying associated with MCT feedings can actually help with feeding tolerance in preterm infants who have trouble handling full feeds.

When MCT Oil Is Not Appropriate

MCT oil is not a supplement you should add to a healthy infant’s diet on your own. The conditions where it provides clear benefit, including fat malabsorption from cholestatic liver disease, long-chain fatty acid oxidation disorders, chylothorax, and refractory epilepsy, are all diagnosed and managed by specialists. For a healthy term infant receiving breast milk or standard formula, there is no evidence that adding MCT oil improves growth, brain development, or any other outcome.

Medium-chain fatty acid oxidation disorders also exist, and for infants with those conditions, MCT supplementation would be harmful rather than helpful, since the body cannot process the medium-chain fats themselves. This is one reason newborn metabolic screening is performed before dietary interventions are started: the treatment for one metabolic disorder can be the trigger for another.

Infants with very short gut (short bowel syndrome) present a nuanced case. While MCTs can be absorbed in a shorter intestinal length than long-chain fats, the rapid absorption and osmotic effects can worsen diarrhea in some of these patients. Clinical teams titrate MCT carefully in short bowel patients rather than defaulting to high-MCT regimens. The biliary atresia data showing an inverse relationship between MCT dose and growth serves as a broader caution: in pediatric nutrition, more is not automatically better, and the dose has to be tailored to the individual infant’s physiology and disease severity.¹⁰

1
PubMed Central. Maternal MCT Oil‐Based Diet in the Treatment of Primary Fetal Pleural Effusion: Case Reports
2
PubMed Central. Medium-chain fatty acid oxidation is independent of l-carnitine in liver and kidney but not in heart and skeletal muscle
3
Gastroenterology. Effect of fat and carbohydrate composition on the gastric emptying of isocaloric feedings in premature infants
4
PubMed Central. Correction of the malabsorption of the preterm infant with a medium-chain triglyceride formula
5
PubMed Central. Efficacy of medium-chain triglyceride oil massage on growth in preterm infants: a randomized controlled trial
6
Cochrane Database of Systematic Reviews. High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
7
PubMed. Medium-chain triglyceride supplementation in preterm infants: A prospective cohort study
8
Indus Journal of Bioscience Research. Role of Oral Medium Chain Triglyceride Oil in Low Birth Weight Neonates: A Randomized Controlled Trial
9
Clinical Nutrition. Medium-chain triglyceride supplementation in children with cholestatic liver disease: A scoping review
10
PubMed Central. Medium-chain triglyceride supplementation in infants with biliary atresia: a review of the evidence for impacts on fat absorption, growth, nutritional status and clinical outcomes
11
PubMed Central. Long-chain fatty acid oxidation disorders and current management strategies
12
PubMed Central. Nutritional Management of Patients with Fatty Acid Oxidation Disorders
13
PubMed Central. DGAT-1 deficiency: Congenital diarrhea and dietary treatment
14
PubMed. The MCT-ketogenic diet as a treatment option in refractory childhood epilepsy: A prospective study with 2-year follow-up
15
PubMed. Essential fatty acid deficiency associated with the use of a medium-chain-triglyceride infant formula in pediatric hepatobiliary disease
16
PubMed Central. Medium chain triglycerides (MCT) formulas in paediatric and allergological practice
17
PubMed. Triacylglycerol Containing Medium-Chain Fatty Acids: Comparison of Human Milk and Infant Formulas on Lipolysis during In Vitro Digestion
18
International Dairy Journal. Triacylglycerol containing medium-chain fatty acids (MCFA-TAG): The gap between human milk and infant formulas
19
PubMed Central. Minimal Effects of Medium-Chain Triglyceride Supplementation on the Intestinal Microbiome Composition of Premature Infants: A Single-Center Pilot Study